When was Healx founded?

Healx was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is Healx located?

Healx is headquartered in Cambridge, United Kingdom. It is registered at 3rd Floor Charter House, 66-68 Hills Road, Cambridge, England, CB2 1LA.

Who is the current CEO of Healx?

Tim Guilliams of Healx. They have also founded 1 company.

Which legal entities is Healx associated with?

Healx is associated with Healx Limited and 1 other.

How many employees does Healx have?

As of Jul 31, 2026, the latest employee count at Healx is 71.

Is Healx a funded company?

Healx is a funded company, having raised a total of $115M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 15, 2015.

How much is Healx worth?

The latest valuation of Healx is £***** as of May 02, 2025.

When was the latest funding round of Healx?

Healx's latest funding was a $***** Series C round on Aug 01, 2024, with participation from 9 investors.

What is the annual revenue of Healx?

Annual revenue of Healx is less than £1M as on Dec 31, 2022

Where does Healx rank among its competitors?

Healx ranks 34th amongst 499 active competitors, of which 153 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Healx, which secured $47M in Aug, 2024.

Who are the top competitors of Healx?

Healx's top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, Healx secured the most recent funding round in August, 2024.

Healx - 2026 Company Profile, Team, Funding, Competitors & Financials

Healx is a series C company based in Cambridge (United Kingdom), founded in 2014 by David Brown and Tim Guilliams. It operates as a Provider of AI-powered drug discovery solutions for rare diseases. Healx has raised $115M in funding from investors like Atomico, Balderton Capital and Amadeus Capital, with a current valuation of £*****. The company has 499 active competitors, including 153 funded and 110 that have exited. Its top competitors include companies like BridgeBio, Alnylam and PTC Therapeutics.

Company Details

Provider of AI-powered drug discovery solutions for rare diseases. It helps identify new drug candidates, repurpose existing compounds, and accelerate rare disease research and development. The company combines machine learning, biomedical knowledge graphs, and expert drug discovery workflows to improve the speed and success rate of bringing treatments to patients.

Website: healx.ai
Social
Email ID: *****@healx.io
Phone Number: +44 **********
Registered Address: 3rd Floor Charter House, 66-68 Hills Road, Cambridge, England, CB2 1LA

Key Metrics

Founded Year

2014

Location

Cambridge, United Kingdom

Stage

Series C

Total Funding

$115M in 6 rounds

Latest Funding Round

Series C, Aug 01, 2024, $*****

Post Money Valuation

£***** as on May 02, 2025

Investors

Atomico & 20 more

Ranked

34^th among 499 active competitors

Annual Revenue

£0 - £1M as on Dec 31, 2022

Employee Count

71 as on Jul 31, 2026

Similar Companies

BridgeBio & 3340 more

View Healx's full profile

Healx is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Healx Limited CIN: 9018507 , Germany, Active	Apr 29, 2014	£0 - £1M (As on Dec 31, 2018)	55 (As on Dec 31, 2024)
Healx Limited CIN: 9018507 , United Kingdom, Active	Apr 29, 2014	£0 - £1M (As on Dec 31, 2022)	46 (As on Dec 31, 2020)

Healx has raised a total funding of $115M over 6 rounds. Its first funding round was on Apr 15, 2015. Its latest funding round was a Series C round on Aug 01, 2024 for $*****. 9 investors participated in its latest round. Healx has 20 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Healx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 01, 2024	7413214	Series C	6486620	6901732	7286399	4990049
2022	9838	Series C	7857	4126	4122	8626
Oct 16, 2019	3535244	Series B	6986758	8083396	Atomico	Intel Capital & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Healx's funding rounds and investors

The founders of Healx are David Brown and Tim Guilliams. Tim Guilliams is the CEO of Healx.

Here are the details of Healx's key team members:

David Brown: Co-Founder of Healx and founder of 1 other company. They serve on the board of 1 company.
Tim Guilliams: Co-Founder & CEO of Healx. They serve on the board of 1 company.

Healx's Board of Directors

Healx's board has 6 active members. David Brown and Tim Guilliams are part of team and Ronjon Nag, Suranga Chandratillake, Jonathan Simon Milner and Laura Elizabeth Connell are independent board members.

Here is the list of Healx's board of directors:

Name	Type	Representing	Status	Duration
David Brown	Team	-	Current	10y 10m
Tim Guilliams	Team	-	Current	12y 3m
Ronjon Nag	Independent board member	-	Current	3y 2m
momizxr	Independent board member	-	Current	5y 3m
yuaktfd	Independent board member	-	Current	5y 1m
jvfy{rc	Independent board member	-	Current	2y 7m

View details of Healx's Founder profiles and Board Members

Healx's employee count trend

Healx has 71 employees as of Jul 26. Here is Healx's employee count trend over the years:

Uncover Healx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Healx include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Healx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	KKR, Viking Global Investors & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates, WuXi AppTec & 16 others	74/100
6th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, T. Rowe Price & 6 others	73/100
7th	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, DCVC & 47 others	72/100
8th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
9th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
10th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
34th	Healx 2014, Cambridge (United Kingdom), Series C	Provider of AI-powered drug discovery solutions for rare diseases	$115M	Atomico, Balderton Capital & 19 others	62/100